Last reviewed · How we verify

Remifentanil, Propofol, and Desflurane

The Cooper Health System · FDA-approved active Small molecule

This is a combination of three anesthetic agents that work together to induce and maintain general anesthesia through different mechanisms: remifentanil provides opioid analgesia, propofol induces sedation via GABA potentiation, and desflurane maintains anesthesia via volatile anesthetic action.

This is a combination of three anesthetic agents that work together to induce and maintain general anesthesia through different mechanisms: remifentanil provides opioid analgesia, propofol induces sedation via GABA potentiation, and desflurane maintains anesthesia via volatile anesthetic action. Used for Induction and maintenance of general anesthesia for surgical procedures.

At a glance

Generic nameRemifentanil, Propofol, and Desflurane
Also known asUltiva, Diprivan, Suprane
SponsorThe Cooper Health System
Drug classGeneral anesthetic combination
TargetMu-opioid receptor (remifentanil); GABA-A receptor (propofol); multiple ion channels and neurotransmitter receptors (desflurane)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Remifentanil is a potent synthetic opioid agonist at mu-opioid receptors providing rapid analgesia and sedation. Propofol is a sedative-hypnotic that enhances inhibitory GABA-A receptor signaling in the central nervous system. Desflurane is a volatile anesthetic that modulates multiple ion channels and neurotransmitter receptors to maintain unconsciousness. Together, these agents provide balanced general anesthesia with rapid onset and offset.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: